Avandia (rosiglitazone), and all diabetes medications that contain rosiglitazone will be taken off the market within the next few months, says the European Medicines Agency (EMA) which has recommended taking it off the market. Specifically, the following brands are involved – Avandia, Avandamet and Avaglim. Yesterday, the FDA (Food and Drug Administration, USA) severely restricted rosiglitazone use and ordered GlaxoSmithKline, (more…)
Posts Tagged ‘rosiglitazone’
Avandia (Rosiglitazone) To Be Taken Off The Market In Europe
Friday, September 24th, 2010
Takeda Responds To Announcement About Suspension Of Rosiglitazone Marketing Authorization In Europe And Restrictions In The U.S.
Friday, September 24th, 2010
Following today’s announcements by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for rosiglitazone in the U.S. and Europe, Takeda Pharmaceuticals North America, Inc. and Takeda Pharmaceuticals Europe Limited (“Takeda”) underscore the company’s commitment to ACTOS® (pioglitazone HCl) and ACTOS-containing medications, and to the millions of people living with type 2 diabetes.
As this (more…)
Diabetes Drugs Avandia (rosiglitazone) And Actos (pioglitazone) Have Same Heart Disease And Death Risks
Wednesday, August 25th, 2010
A new analysis of diabetes medications Avandia (rosiglitazone) and Actos (pioglitazone) revealed that the risk of heart attack and/or heart failure, or death were the same, approximately 4%. The study has been published in the latest issue of Circulation: Cardiovascular Quality and Outcomes , an American Heart Association journal.
Takeda Pharmacuetical Co. makes Actos, while GlaxoSmithKline (GSK) makes Avandia. (more…)